MedTrace Logo

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

NCT07160790 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 321

Last updated 2025-09-08

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD

Conditions

  • Non-erosive Gastroesophageal Reflux Disease

Interventions

DRUG

JP-1366 + placebo

taking JP-1366 + placebo

DRUG

Placebo + Placebo

taking placebo + placebo

Sponsors & Collaborators

  • Onconic Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-02
Primary Completion
2026-06-30
Completion
2026-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07160790 on ClinicalTrials.gov